Eidos Therapeutics (EIDX) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of Eidos Therapeutics (NASDAQ:EIDX) from a sell rating to a hold rating in a research report released on Monday.

According to Zacks, “Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States. “

Several other equities analysts have also weighed in on the stock. Bank of America cut their price objective on shares of Eidos Therapeutics from $24.00 to $13.00 and set a neutral rating on the stock in a report on Monday, October 1st. JPMorgan Chase & Co. started coverage on shares of Eidos Therapeutics in a report on Monday, July 16th. They issued an overweight rating and a $36.00 target price on the stock. Finally, Barclays started coverage on shares of Eidos Therapeutics in a report on Monday, July 16th. They issued an overweight rating and a $32.00 target price on the stock.

Shares of NASDAQ EIDX opened at $10.03 on Monday. Eidos Therapeutics has a fifty-two week low of $8.89 and a fifty-two week high of $24.75.

Eidos Therapeutics (NASDAQ:EIDX) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($1.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($1.15). On average, analysts expect that Eidos Therapeutics will post -2.09 EPS for the current year.

Several hedge funds have recently modified their holdings of EIDX. Dean Capital Investments Management LLC bought a new stake in shares of Eidos Therapeutics during the second quarter worth $528,000. Board of Trustees of The Leland Stanford Junior University bought a new stake in shares of Eidos Therapeutics during the second quarter worth $3,642,000. BlackRock Inc. bought a new stake in shares of Eidos Therapeutics during the second quarter worth $3,051,000. Janus Henderson Group PLC bought a new stake in shares of Eidos Therapeutics during the second quarter worth $6,511,000. Finally, Tiverton Asset Management LLC bought a new stake in shares of Eidos Therapeutics during the second quarter worth $163,000. 22.97% of the stock is owned by institutional investors.

About Eidos Therapeutics

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Further Reading: What is the balance sheet?

Get a free copy of the Zacks research report on Eidos Therapeutics (EIDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply